Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739690 | 1.00 | CYP2A13 (0.51) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL23213421 | 0.87 | GSPT1 (0.41) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL29796053 | 0.87 | GSPT1 (0.41) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL23240235 | 0.84 | CYP2A13 (0.53) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL23239911 | 0.84 | CYP2A13 (0.54) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL29716296 | 0.83 | LMNA (0.50) | KMT2AMEN1GAAMAPTSMN1; SMN2 | |
| SCHEMBL23213589 | 0.83 | LMNA (0.50) | KMT2AMEN1GAAMAPTSMN1; SMN2 | |
| SCHEMBL29739597 | 0.82 | CYP2A13 (0.50) | CYP2A13KMT2AMEN1CYP2C9ALOX15 | |
| SCHEMBL26739617 | 0.79 | CYP2A13 (0.49) | CYP2A13KMT2AMEN1GAAMAPT | |
| SCHEMBL23213849 | 0.78 | PDCD1 (0.38) | CYP2A13MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323349-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051937-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022219412-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | MONTE ROSA THERAPEUTICS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP2A13 294/4885KMT2A 1951/4885MEN1 186/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CYP2A13 294/4885KMT2A 1951/4885MEN1 186/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CYP2A13 458/4885KMT2A 3292/4885MEN1 1094/4885 |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | CYP2A13 4778/4885KMT2A 3745/4885MEN1 196/4885 |
| US-20240051937-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | GSPT2, GSPT1, NMT2 | CYP2A13 1098/4885KMT2A 2816/4885MEN1 243/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CYP2A13 303/4885KMT2A 1988/4885MEN1 180/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | CYP2A13 403/4885KMT2A 2523/4885MEN1 598/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP2A13 294/4885KMT2A 1951/4885MEN1 186/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | CYP2A13 4419/4885KMT2A 1755/4885MEN1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.